Get the Stockscreener App
11.43
4.67%
-0.56
After Hours:
11.03
-0.40
-3.50%
Ernexa Therapeutics Inc stock is traded at $11.43, with a volume of 79,680.
It is down -4.67% in the last 24 hours and up +138.50% over the past month.
Ernexa Therapeutics Inc is a preclinical-stage synthetic allogeneic iMSC therapy company developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its main product candidate, ERNA-101, capitalizes on the intrinsic tumor-homing ability of MSCs (mesenchymal stem cells) to slip through the tumor's defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment. The firm's initial focus is to develop ERNA-101 in platinum-resistant ovarian cancer. Through another product candidate, ERNA-201, it is investigating anti-inflammatory cytokine (IL-10) secreting iMSCs in autoimmune disorders like rheumatoid arthritis. The company operates in a single reportable segment, the research and development of cellular therapies.
See More
Previous Close:
$11.99
Open:
$11.75
24h Volume:
79,680
Relative Volume:
0.05
Market Cap:
$13.33M
Revenue:
$1,000
Net Income/Loss:
$-14.08M
P/E Ratio:
-0.4778
EPS:
-23.9199
Net Cash Flow:
$-7.05M
1W Performance:
-0.17%
1M Performance:
+138.50%
6M Performance:
-66.87%
1Y Performance:
-86.63%
1-Day Range:
$10.88
$11.96
1-Week Range:
$10.67
$13.00
52-Week Range:
$3.1829
$91.54
Ernexa Therapeutics Inc Stock (ERNA) Company Profile
Name
Ernexa Therapeutics Inc
Sector
Industry
Phone
(617) 798-6700
Address
1035 CAMBRIDGE STREET, CAMBRIDGE
Compare ERNA vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ERNA
Ernexa Therapeutics Inc
|
11.43 | 13.98M | 1,000 | -14.08M | -7.05M | -23.92 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ernexa Therapeutics Inc Stock (ERNA) Latest News
Ernexa Therapeutics Unveils Breakthrough Preclinical Results: ERNA-101 Achieves 100% Survival and Complete Tumor Elimination in Ovarian Cancer Models - BioInformant
Ernexa Therapeutics Inc. (ERNA) Q3 2023 Earnings: Narrowing Losses Amidst Pipeline ProgressRevenue Report - Newser
Ernexa Therapeutics (ERNA) Q3 2023 Earnings: Deepening Losses and Clinical-Phase Uncertainty Weigh on SharesPro Level Trade Signals - Newser
Ernexa Therapeutics Q3 2023 Earnings: Losses Deepen as Stock Declines, No Revenue ReportedGuidance Revision Trend - Newser
Ernexa Therapeutics (ERNA) Slips 3.8% as Shares Test Key Support Near $11.39Sentiment Extreme - Newser
ERNA stock shoots up 140% in a month: Here's what you should know - MSN
Clear Street exits ownership reporting for Ernexa Therapeutics (NASDAQ: ERNA) - Stock Titan
ERNA Stock Shoots Up 140% in a Month: Here's What You Should Know - sharewise.com
Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Featuring Dr. Elena Ratner Highlighting Ovarian Cancer Landscape and ERNA-101 Opportunity - The Globe and Mail
Ernexa Therapeutics stock climbs on breakthrough preclinical data - MSN
ernexa therapeutics inc. Earnings dates - RTTNews
Ernexa Therapeutics (ERNA): Trustees report 66,751 shares, 5.6% stake - Stock Titan
ERNA stock almost doubled in value today – smashing rally leads to 7 trading halts - MSN
Ernexa Therapeutics Inc (ERNA) Stock Price, Quote, News & History - Benzinga
Ernexa Therapeutics (ERNA) 10K Form and Latest SEC Filings 2026 - MarketBeat
ERNA | Ernexa Therapeutics Inc. Common Analyst Forecasts - Quiver Quantitative
Bleichroeder LP discloses 6.86% stake in Ernexa Therapeutics (ERNA) - Stock Titan
Clear Street LLC reports 12.8% stake in Ernexa (NASDAQ: ERNA) - Stock Titan
Ernexa Therapeutics (ERNA) amendment: 118,342 shared holdings; 48,000 warrants noted - Stock Titan
Ernexa Stock Is Jumping Today: What's Going On? - Sahm
Nasdaq Dips Over 1%; US Inflation Surges To 3.8% In April - Sahm
Ernexa Therapeutics (ERNA) Stock Soars 78% Following Q1 Earnings and Pipeline Update - MEXC
Ernexa Stock’s 58% Jump Shows How Fast a Tiny Biotech Can Reprice on Ovarian-Cancer Hopes - TechStock²
Ernexa Therapeutics (ERNA) Stock Jumps Over 78% as Q1 Loss Narrows - MEXC
Ernexa Therapeutics (ERNA) Stock Soars 78% Following Improved Q1 Financials - parameter.io
Ernexa Therapeutics (ERNA) Stock Soars 78% Following Improved Q1 Earnings Report - MoneyCheck
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
ERNA Stock Almost Doubled In Value Today – Smashing Rally Leads To 7 Trading Halts - Stocktwits
[ARS] Ernexa Therapeutics Inc. SEC Filing - Stock Titan
Ernexa Therapeutics (NASDAQ: ERNA) details 2026 meeting, equity plan and insider ownership - Stock Titan
Ernexa Therapeutics Inc. 1Q 2026: Net loss $(5.51)M, EPS $(6.95) — 10-Q Summary - TradingView
Ernexa Therapeutics (ERNA) trims Q1 2026 loss, boosts cash with $10.5M offering - Stock Titan
Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Highlighting Ovarian Cancer Landscape and Lead Candidate ERNA-101 - Weekly Voice
Ernexa Therapeutics Releases Virtual Investor KOL Connect - GlobeNewswire
ERNA shares fall 3.71% as Ernexa Therapeutics posts Q3 loss of $1.03 per share.Shared Trade Alerts - Newser
Ernexa Therapeutics Inc.: Target Price Consensus and Analysts Recommendations | ERNA | US1140824079 - marketscreener.com
symbol__ Stock Quote Price and Forecast - CNN
ERNA Stock Skyrockets After ERNA-101 Delivers Tumor Clearance - timothysykes.com
Top Small Cap Stocks To Add to Your WatchlistMay 6th - MarketBeat
Why Ernexa Therapeutics Stock Jumped After ERNA-101 Ovarian Cancer Survival Data - TechStock²
What separates Ernexa Therapeutics (ERNA) from the pack? (Smart Money Flows) 2026-05-06Bollinger Bands - Newser
ERNA Stock Surged 60% Today – Here’s Why Retail Is Buzzing About Ernexa’s Ovarian Cancer Trial Results - Stocktwits
Ernexa Therapeutics Stock Climbs On Breakthrough Preclinical Data - Benzinga
Ernexa Therapeutics (ERNA) Preclinical Data Shows 100% Survival and Complete Tumor Clearance in Ovarian Cancer Models - Yahoo Finance
ERNA Stock Explodes Higher As Tiny Biotech Draws Trader Focus - StocksToTrade
ERNA Stock Rockets Higher As Traders Target Breakout Move - timothysykes.com
Ernexa reports preclinical data for ovarian cancer therapy - Investing.com
Ernexa reports preclinical data for ovarian cancer therapy By Investing.com - Investing.com Canada
Ernexa stock surges 40% on ovarian cancer trial results By Investing.com - Investing.com Canada
Ernexa Therapeutics Inc Stock (ERNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Ernexa Therapeutics Inc Stock (ERNA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Cherington Charles | 10% Owner |
Jun 09 '25 |
Buy |
0.10 |
21,241,163 |
2,221,826 |
41,659,743 |
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):